CY1117883T1 - Φαρμακευτικες συνθεσεις διπλης δρασης με βαση υπερδομες απο ανταγωνιστη/αποκλειστη υποδοχεα αγγειοτενσινης (arb) και αναστολεα ουδετερης ενδοπεπτιδασης (nep) - Google Patents
Φαρμακευτικες συνθεσεις διπλης δρασης με βαση υπερδομες απο ανταγωνιστη/αποκλειστη υποδοχεα αγγειοτενσινης (arb) και αναστολεα ουδετερης ενδοπεπτιδασης (nep)Info
- Publication number
- CY1117883T1 CY1117883T1 CY20161100778T CY161100778T CY1117883T1 CY 1117883 T1 CY1117883 T1 CY 1117883T1 CY 20161100778 T CY20161100778 T CY 20161100778T CY 161100778 T CY161100778 T CY 161100778T CY 1117883 T1 CY1117883 T1 CY 1117883T1
- Authority
- CY
- Cyprus
- Prior art keywords
- arb
- risk
- container
- double
- component
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000006835 compression Effects 0.000 abstract 3
- 238000007906 compression Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 abstract 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- -1 pentanyl Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Στερεές μορφές δοσολογίας από του στόματος, ιδιαίτερα δισκία, μιας φαρμακευτικής σύνθεσης που περιέχει ένα υπερμοριακό σύμπλοκο μπορούν να παρασκευαστούν από μια διαδικασία άμεσης συμπίεσης ή μια διαδικασία συμπίεσης όπως είναι η συμπίεσης ελάστρου. Τέτοιες στερεές μορφές δοσολογίας από του στόματος χαρακτηρίζονται από ένα προφίλ άμεσης απελευθέρωσης που επιτρέπει ταχεία αποδέσμευση του θεραπευτικού παράγοντα. Ένα ιδιαίτερα χρήσιμο υπερ-μοριακό σύμπλοκο είναι το τρινάτριο [3-((1S,3R)-1-διφαινυλ-4-υλομεθυλ- 3- αιθοξυκαρβονυλο- 1- βουτυλκαρβαμοϋλο) προπιονικό-(S) -3'-μεθυλο-2' (πεντανυλο {2"-(τετραζολ-5-υλικό) διφαινυλ-4'-υλο-μεθυλ}αμινο)βουτυρικός]ημιπενταϋδρίτης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98566807P | 2007-11-06 | 2007-11-06 | |
EP08848154.4A EP2217205B1 (en) | 2007-11-06 | 2008-11-04 | Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117883T1 true CY1117883T1 (el) | 2017-05-17 |
Family
ID=40451030
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100426T CY1116280T1 (el) | 2007-11-06 | 2015-05-14 | Φαρμακευτικες συνθεσεις διπλης δρασης με βαση υπερδομες απο ανταγωνιστη/αποκλειστη υποδοχεα αγγειοτενσινης (arb) και αναστολεα ουδετερης ενδοπεπτιδασης (νερ) |
CY20161100778T CY1117883T1 (el) | 2007-11-06 | 2016-08-08 | Φαρμακευτικες συνθεσεις διπλης δρασης με βαση υπερδομες απο ανταγωνιστη/αποκλειστη υποδοχεα αγγειοτενσινης (arb) και αναστολεα ουδετερης ενδοπεπτιδασης (nep) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100426T CY1116280T1 (el) | 2007-11-06 | 2015-05-14 | Φαρμακευτικες συνθεσεις διπλης δρασης με βαση υπερδομες απο ανταγωνιστη/αποκλειστη υποδοχεα αγγειοτενσινης (arb) και αναστολεα ουδετερης ενδοπεπτιδασης (νερ) |
Country Status (34)
Country | Link |
---|---|
US (3) | US20100267786A1 (el) |
EP (4) | EP2295035B1 (el) |
JP (2) | JP5653218B2 (el) |
KR (2) | KR101700062B1 (el) |
CN (2) | CN103251587A (el) |
AR (1) | AR069184A1 (el) |
AU (1) | AU2008324878B2 (el) |
BR (1) | BRPI0823505A2 (el) |
CA (1) | CA2703598C (el) |
CL (1) | CL2008003298A1 (el) |
CY (2) | CY1116280T1 (el) |
DK (3) | DK2217205T3 (el) |
EC (1) | ECSP10010160A (el) |
ES (3) | ES2536514T3 (el) |
FI (1) | FI3067043T3 (el) |
GT (1) | GT201000131A (el) |
HK (3) | HK1143529A1 (el) |
HR (3) | HRP20230178T3 (el) |
HU (2) | HUE028866T2 (el) |
IL (3) | IL262990B2 (el) |
JO (1) | JOP20080499B1 (el) |
MA (1) | MA31797B1 (el) |
MX (1) | MX2010004930A (el) |
MY (1) | MY153730A (el) |
NZ (1) | NZ584686A (el) |
PE (2) | PE20141072A1 (el) |
PL (3) | PL2295035T3 (el) |
PT (3) | PT2295035T (el) |
RU (1) | RU2493844C3 (el) |
SG (1) | SG185951A1 (el) |
SI (3) | SI3067043T1 (el) |
TN (1) | TN2010000200A1 (el) |
TW (1) | TWI484982B (el) |
WO (1) | WO2009061713A1 (el) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20230178T3 (hr) | 2007-11-06 | 2023-03-31 | Novartis Ag | Farmaceutski pripravci temeljeni na nadgradnjama antagonista/blokatora angiotenzinskog receptora (arb) i inhibitoru neutralne endopeptidaze (nep) |
EP2435402B1 (en) | 2009-05-28 | 2016-04-13 | Novartis AG | Substituted aminobutyric derivatives as neprilysin inhibitors |
NZ596304A (en) | 2009-05-28 | 2014-01-31 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
US20130158088A1 (en) | 2010-08-24 | 2013-06-20 | Novartis Ag | Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
KR20200111822A (ko) | 2012-08-24 | 2020-09-29 | 노파르티스 아게 | 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제 |
EP2956445A1 (en) | 2013-02-14 | 2015-12-23 | Novartis AG | Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy |
LT2956464T (lt) | 2013-02-14 | 2018-07-10 | Novartis Ag | Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai |
SI3038654T1 (sl) | 2013-08-26 | 2020-02-28 | Novartis Ag | Nova uporaba |
JP2016530282A (ja) * | 2013-08-26 | 2016-09-29 | ノバルティス アーゲー | 新規使用 |
WO2015154673A1 (en) * | 2014-04-10 | 2015-10-15 | Zhaoyin Wang | Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases |
CN105461647B (zh) * | 2014-09-28 | 2018-06-29 | 四川海思科制药有限公司 | 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途 |
CN105873586B (zh) | 2014-12-08 | 2019-09-13 | 苏州晶云药物科技股份有限公司 | 一种包含缬沙坦和ahu377的三钠盐超分子复合物的晶型及其制备方法 |
CN104473938B (zh) * | 2014-12-30 | 2017-06-09 | 北京瑞都医药科技有限公司 | 一种治疗慢性心衰药物及其制备方法 |
CN104826115A (zh) * | 2015-04-19 | 2015-08-12 | 浙江巨泰药业有限公司 | 一种抗心衰药物组合物及其制备方法 |
FI3294283T3 (fi) | 2015-05-11 | 2023-05-24 | Novartis Ag | Sakubitriili-valsartaani-annostusohjelma sydämen vajaatoiminnan hoitamiseksi |
JP2018516267A (ja) | 2015-05-29 | 2018-06-21 | ノバルティス アーゲー | 代謝性疾患を治療するためのサクビトリルおよびバルサルタン |
CN106309388A (zh) * | 2015-06-30 | 2017-01-11 | 深圳信立泰药业股份有限公司 | 一种用于心衰治疗的药物组合物及其制备方法 |
WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
CN106176724A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种稳定的固体药物组合物及其制备方法 |
CN106176725A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种提高稳定性的药物组合物及其制备方法和用途 |
CN105997994A (zh) * | 2015-07-11 | 2016-10-12 | 凌莉 | 一种固体口服型制剂及其制备方法 |
CN106074421A (zh) * | 2015-07-11 | 2016-11-09 | 凌莉 | 一种提高稳定性的药物组合物 |
CN105997993B (zh) * | 2015-07-11 | 2018-03-30 | 麦丽芳 | 一种用于心血管疾病治疗的固体口服型制剂及其制备方法 |
CN106176723A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种固体药物组合物及其制备方法 |
WO2017012600A1 (en) | 2015-07-20 | 2017-01-26 | Zentiva, K.S. | A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof |
CN106397249A (zh) * | 2015-08-03 | 2017-02-15 | 深圳信立泰药业股份有限公司 | 一种高稳定性lcz696结晶粉末及其制备方法 |
WO2017037596A1 (en) * | 2015-08-28 | 2017-03-09 | Dr. Reddy's Laboratories Limited | Amorphous solid dispersion of lcz-696 |
EP3355880A1 (en) | 2015-08-28 | 2018-08-08 | Novartis AG | New use |
US20180303799A1 (en) * | 2015-10-16 | 2018-10-25 | Shenzhen Salubris Pharmaceuticals Co., Ltd | An Oral Preparation for the Treatment of Cardiovascular Disease and Its Preparation Method |
CN105669581B (zh) * | 2015-11-09 | 2017-03-22 | 成都苑东生物制药股份有限公司 | 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物 |
WO2017085573A1 (en) * | 2015-11-20 | 2017-05-26 | Lupin Limited | Amorphous sacubitril-valsartan complex and process for preparation thereof |
CN105330609B (zh) * | 2015-12-07 | 2017-12-22 | 南京正大天晴制药有限公司 | 一种制备lcz696的方法 |
CN105929031B (zh) * | 2015-12-18 | 2018-08-21 | 重庆两江药物研发中心有限公司 | 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法 |
CN105935358B (zh) * | 2015-12-18 | 2019-06-07 | 重庆两江药物研发中心有限公司 | 一种沙库比曲缬沙坦缓释剂及其制备方法 |
CN106905253B (zh) * | 2015-12-23 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 一种超分子复合物的结晶 |
CN108601741B (zh) * | 2016-02-03 | 2022-05-24 | 诺华股份有限公司 | 有机化合物的盖伦制剂 |
US10722471B2 (en) * | 2016-02-03 | 2020-07-28 | Novartis Ag | Galenic formulations of organic compounds |
CN105748420B (zh) * | 2016-03-04 | 2018-11-06 | 山东省药学科学院 | 一种治疗心力衰竭的lcz696缓释骨架片的制备方法 |
CN105902506A (zh) * | 2016-06-12 | 2016-08-31 | 佛山市腾瑞医药科技有限公司 | 一种沙卡布曲缬沙坦制剂及其应用 |
WO2018069937A1 (en) | 2016-10-13 | 2018-04-19 | Mylan Laboratories Limited | Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof |
ES2890573T3 (es) * | 2017-03-31 | 2022-01-20 | Tiefenbacher Alfred E Gmbh & Co Kg | Producto extruido de fusión en caliente estable que contiene valsartán y sacubitrilo |
WO2018178295A1 (en) | 2017-03-31 | 2018-10-04 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Stable hot-melt extrudate containing valsartan and sacubitril |
WO2018211479A1 (en) | 2017-05-19 | 2018-11-22 | Lupin Limited | Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof |
US11382866B2 (en) | 2017-07-06 | 2022-07-12 | Mankind Pharma Ltd. | Fixed dose pharmaceutical composition of valsartan and sacubitril |
PL3658122T3 (pl) | 2017-07-28 | 2021-10-18 | Synthon B.V. | Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan |
WO2019073062A1 (en) | 2017-10-13 | 2019-04-18 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | TABLET CONTAINING VALSARTAN AND SACUBITRIL |
WO2019180735A1 (en) * | 2018-03-19 | 2019-09-26 | Natco Pharma Limited | Stable pharmaceutical compositions comprising sacubitril-valsartan complex |
WO2019246503A1 (en) | 2018-06-22 | 2019-12-26 | Ideaz, Llc | Diphenyl tablets and methods of preparing the same |
CA3110152A1 (en) | 2018-08-23 | 2020-02-27 | Novartis Ag | New pharmaceutical use for the treatment of heart failure |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
EP3766484B1 (en) | 2019-07-19 | 2021-08-25 | Zentiva, K.S. | Solid pharmaceutical dosage form comprising valsartan and sacubitril |
KR102545274B1 (ko) | 2020-02-26 | 2023-06-20 | 에리슨제약(주) | 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법 |
KR20210120560A (ko) | 2020-03-27 | 2021-10-07 | 주식회사 유영제약 | 고함량의 주성분을 포함하는 정제 및 그 제조방법 |
KR20210138510A (ko) | 2020-05-12 | 2021-11-19 | 에리슨제약(주) | 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제 |
KR20220091767A (ko) | 2020-12-24 | 2022-07-01 | 주식회사 보령 | 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물 |
KR102486815B1 (ko) | 2021-01-20 | 2023-01-10 | 주식회사 대웅제약 | Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US607893A (en) | 1898-07-26 | Automatic switch-operating machine | ||
US607355A (en) | 1898-07-12 | Carrier for bicycles | ||
US608220A (en) | 1898-08-02 | Mechanical movement | ||
US735093A (en) | 1903-01-31 | 1903-08-04 | Oscar Greenwald | Elevator-cable guard. |
GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
US6558699B2 (en) * | 1997-11-17 | 2003-05-06 | Smithkline Beecham Corporation | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
KR100597922B1 (ko) * | 1997-11-17 | 2006-07-10 | 스미스클라인 비참 코포레이션 | 고용량 약물 로딩 속효성 및 변형 방출형 경구 투여용제형 및 그의 제조 방법 |
WO1999065500A1 (en) * | 1998-06-17 | 1999-12-23 | Bristol-Myers Squibb Company | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
TR200805741T2 (tr) * | 1998-12-23 | 2008-10-21 | Novartis Ag | At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@ |
DE60135560D1 (de) | 2000-07-19 | 2008-10-09 | Novartis Ag | Valsartan salze |
SI1467728T1 (sl) | 2002-01-17 | 2008-02-29 | Novartis Ag | Farmacevtski sestavki vkljucujoci valsartan in NEP inhibitorje |
US7468390B2 (en) * | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
JP3751287B2 (ja) * | 2002-03-27 | 2006-03-01 | バイエル薬品株式会社 | 小型化されたニフェジピン有核錠剤 |
WO2003089417A1 (en) | 2002-04-15 | 2003-10-30 | Dr. Reddy's Laboratories Limited | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan) |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
ATE393764T1 (de) | 2003-03-17 | 2008-05-15 | Teva Pharma | Polymorphe formen von valsartan |
JP2009513543A (ja) * | 2003-07-16 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | クロルタリドンの組み合わせ |
GB0402262D0 (en) * | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
AU2006307470A1 (en) * | 2005-10-27 | 2007-05-03 | Lupin Limited | Pharmaceutical formulation of losartan |
WO2007052307A2 (en) | 2005-10-31 | 2007-05-10 | Lupin Limited | Stable solid oral dosage forms of valsartan |
WO2007056342A2 (en) | 2005-11-07 | 2007-05-18 | Stryker Corporation | Patient handling device including local status indication, one-touch fowler angle adjustment, and power-on alarm configuration |
AU2006311723A1 (en) | 2005-11-08 | 2007-05-18 | Novartis Ag | Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent |
AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
EP1897537A1 (en) * | 2006-09-04 | 2008-03-12 | Novartis AG | Composition comprising an angiotensin II receptor antagonist |
HRP20230178T3 (hr) | 2007-11-06 | 2023-03-31 | Novartis Ag | Farmaceutski pripravci temeljeni na nadgradnjama antagonista/blokatora angiotenzinskog receptora (arb) i inhibitoru neutralne endopeptidaze (nep) |
-
2008
- 2008-11-04 HR HRP20230178TT patent/HRP20230178T3/hr unknown
- 2008-11-04 EP EP10173506.6A patent/EP2295035B1/en not_active Revoked
- 2008-11-04 CA CA2703598A patent/CA2703598C/en active Active
- 2008-11-04 PL PL10173506.6T patent/PL2295035T3/pl unknown
- 2008-11-04 AU AU2008324878A patent/AU2008324878B2/en active Active
- 2008-11-04 PT PT101735066T patent/PT2295035T/pt unknown
- 2008-11-04 SG SG2012081394A patent/SG185951A1/en unknown
- 2008-11-04 JO JOP/2008/0499A patent/JOP20080499B1/ar active
- 2008-11-04 RU RU2010123027A patent/RU2493844C3/ru active
- 2008-11-04 SI SI200832204T patent/SI3067043T1/sl unknown
- 2008-11-04 PT PT88481544T patent/PT2217205E/pt unknown
- 2008-11-04 EP EP22200982.1A patent/EP4186491A1/en active Pending
- 2008-11-04 MX MX2010004930A patent/MX2010004930A/es active IP Right Grant
- 2008-11-04 US US12/741,251 patent/US20100267786A1/en not_active Abandoned
- 2008-11-04 MY MYPI2010001722A patent/MY153730A/en unknown
- 2008-11-04 CN CN2013101540642A patent/CN103251587A/zh active Pending
- 2008-11-04 EP EP16157767.1A patent/EP3067043B1/en active Active
- 2008-11-04 IL IL262990A patent/IL262990B2/en unknown
- 2008-11-04 DK DK08848154.4T patent/DK2217205T3/en active
- 2008-11-04 PE PE2013002393A patent/PE20141072A1/es active IP Right Grant
- 2008-11-04 HU HUE10173506A patent/HUE028866T2/en unknown
- 2008-11-04 SI SI200831654A patent/SI2295035T1/sl unknown
- 2008-11-04 NZ NZ584686A patent/NZ584686A/xx unknown
- 2008-11-04 PT PT161577671T patent/PT3067043T/pt unknown
- 2008-11-04 PL PL08848154T patent/PL2217205T3/pl unknown
- 2008-11-04 ES ES08848154.4T patent/ES2536514T3/es active Active
- 2008-11-04 SI SI200831427T patent/SI2217205T1/sl unknown
- 2008-11-04 JP JP2010533185A patent/JP5653218B2/ja active Active
- 2008-11-04 PE PE2008001886A patent/PE20091390A1/es not_active Application Discontinuation
- 2008-11-04 EP EP08848154.4A patent/EP2217205B1/en not_active Revoked
- 2008-11-04 CN CN200880114940A patent/CN101848700A/zh active Pending
- 2008-11-04 PL PL16157767.1T patent/PL3067043T3/pl unknown
- 2008-11-04 AR ARP080104826A patent/AR069184A1/es not_active Application Discontinuation
- 2008-11-04 KR KR1020157033633A patent/KR101700062B1/ko active IP Right Review Request
- 2008-11-04 ES ES10173506.6T patent/ES2587336T3/es active Active
- 2008-11-04 ES ES16157767T patent/ES2939163T3/es active Active
- 2008-11-04 DK DK10173506.6T patent/DK2295035T3/en active
- 2008-11-04 BR BRPI0823505-8A patent/BRPI0823505A2/pt not_active Application Discontinuation
- 2008-11-04 FI FIEP16157767.1T patent/FI3067043T3/fi active
- 2008-11-04 HU HUE16157767A patent/HUE061321T2/hu unknown
- 2008-11-04 DK DK16157767.1T patent/DK3067043T3/da active
- 2008-11-04 WO PCT/US2008/082324 patent/WO2009061713A1/en active Application Filing
- 2008-11-04 KR KR1020107009852A patent/KR101589317B1/ko active IP Right Review Request
- 2008-11-05 CL CL2008003298A patent/CL2008003298A1/es unknown
- 2008-11-05 TW TW097142724A patent/TWI484982B/zh active
-
2010
- 2010-04-19 IL IL205208A patent/IL205208A/en active IP Right Grant
- 2010-04-30 TN TN2010000200A patent/TN2010000200A1/fr unknown
- 2010-04-30 MA MA32803A patent/MA31797B1/fr unknown
- 2010-05-05 GT GT201000131A patent/GT201000131A/es unknown
- 2010-05-06 EC EC2010010160A patent/ECSP10010160A/es unknown
- 2010-10-19 HK HK10109891.9A patent/HK1143529A1/xx not_active IP Right Cessation
- 2010-10-19 HK HK11107642.4A patent/HK1149721A1/zh not_active IP Right Cessation
-
2014
- 2014-08-12 JP JP2014164022A patent/JP2015038069A/ja not_active Withdrawn
-
2015
- 2015-04-28 HR HRP20150459TT patent/HRP20150459T1/hr unknown
- 2015-05-14 CY CY20151100426T patent/CY1116280T1/el unknown
-
2016
- 2016-08-02 HR HRP20160988TT patent/HRP20160988T1/hr unknown
- 2016-08-08 CY CY20161100778T patent/CY1117883T1/el unknown
- 2016-10-31 HK HK16112495.7A patent/HK1224195A1/zh unknown
-
2017
- 2017-01-03 IL IL249922A patent/IL249922A0/en unknown
-
2020
- 2020-12-02 US US17/109,716 patent/US20210085631A1/en not_active Abandoned
-
2023
- 2023-05-09 US US18/314,745 patent/US20240115536A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117883T1 (el) | Φαρμακευτικες συνθεσεις διπλης δρασης με βαση υπερδομες απο ανταγωνιστη/αποκλειστη υποδοχεα αγγειοτενσινης (arb) και αναστολεα ουδετερης ενδοπεπτιδασης (nep) | |
CY1114566T1 (el) | Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα | |
AR109571A2 (es) | Composición de trazodona para administración una vez por día | |
CY1117895T1 (el) | Στερεα φαρμακευτικα σκευασματα που περιεχουν bibw 2992 | |
MX2009001711A (es) | Formulaciones de liberacion sostenida de topiramato. | |
TW200637874A (en) | Peptides with neuropeptide-2 receptor (Y2R) agonist activity | |
NO20084256L (no) | DPP IV inhibitorformuleringer | |
CY1118180T1 (el) | Μεθοδος για παρασκευη στερεας φαρμακευτικης συνθεσης | |
CL2007001918A1 (es) | Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras. | |
CY1108973T1 (el) | Ξηρα κοκκοποιημενη συνθεση η οποια περιλαμβανει εμτρισιταβινη και τενοφοβιρη df | |
BRPI0915084B8 (pt) | composto, e, composição farmacêutica | |
GT200600258A (es) | Derivados de n-(piridin-2-il)-sulfonamida | |
ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
NO20082768L (no) | Levodopa prodroge mesylat, sammensetninger og anvendelser derav | |
FR2903312B1 (fr) | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament | |
NO20074933L (no) | Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat | |
EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
ECSP099442A (es) | Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona | |
ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
AR077546A1 (es) | Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos | |
GB0524814D0 (en) | Compounds | |
NO20082047L (no) | Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme | |
MX2008001211A (es) | Derivados de bencilpiperazina y su uso medico. | |
CY1109405T1 (el) | Στοματο-διασπειρομενα δισκια δομπεριδονης |